The Journey of Gemtuzumab in AML

This chapter chronicles the complex history of gemtuzumab, an antibody-drug conjugate for acute myeloid leukemia, from its initial approval and market withdrawal to its re-approval based on new meta-analysis findings. It emphasizes the critical studies and data interpretations that influenced its resurgence and the ongoing discussions about treatment strategies for patients.